News

December 2025 psychiatry updates: Teva files TEV-‘749 for schizophrenia, lumateperone boosts MDD outcomes, AGA tied to mental health, and a look back at 2025 advances.

Catch up with major FDA decisions, critical conference news, and more.

An audio recap of the top 5 stories in healthcare news from the week of 12/28-1/3.

The data may help to guide informed decision-making related to dupilumab use and management of severe atopic dermatitis in infants and young children.

December highlights: FDA approval of berotralstat for pediatric HAE, phase 3 RAPIDe-3 results, and allergy field spotlights in our This Year in Medicine series.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and CRLs, in this week’s essential news roundup.

A recent retrospective cohort analysis of the ACCORD phase 3 study has revealed a correlation between higher index values and increased mortality risk.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking news of oral semaglutide's approval and its cardioprotective benefits.

In December 2025, intervention strategies, dialysis modalities, and kidney transplantation data provided insight to improve renal care for clinicians.

Nurse practitioners play a key role in allergy and asthma care using specific IgE blood testing to identify triggers, improve outcomes, and ease shortages.

The 2025 cholangitis year in review covers PBC and PSC advances, FDA designations, trial data, and evolving treatment pathways.

This episode spotlights how advancements in 2025, including data from AASLD 2025, set the stage for future standards of care in cholestatic liver disease.

Investigators explored the measurement properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) among patients with chronic skin disease.

The CRL notes that additional mechanistic and natural history data have not altered the previous review conclusions.

2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.

The novel oral NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor has indicated its efficacy and safety across 3 clinical trials.

The FDA has issued a CRL for selective cortisol modulator relacorilant, citing a need for more evidence of effectiveness.

The FDA has approved oral neurokinin-1 receptor antagonist tradipitant for the prevention of motion sickness, marking the first approval in decades.

From FDA decisions to late-phase trial readouts and updated practice guidelines, 2025 delivered clinically actionable insights across sleep conditions.

Catch up on the most impactful headlines in hormonal disorders from all of 2025 with our Year in Review.

C3G treatment advances in 2025 with FDA approvals of iptacopan and pegcetacoplan, offering disease-modifying options

FDA clears first human umbilical cord–derived sheet device, Theracor, for wound Care

In this end-of-year reel, HCPLive has showcased several key highlights from the Skin of Color Savvy podcast in 2025.

The FDA grants breakthrough therapy designation for ulizacaltamine for the treatment of essential tremor.

In 2025, psychiatry saw major FDA approvals, novel treatments, and pivotal clinical updates that are transforming care for depression, ADHD, schizophrenia, and anxiety.

The gastroenterology year in review covers FDA approvals, IBD breakthroughs, IL-23 therapies, new guidelines, and advances in GI care.

Catch up on the most impactful headlines in HF from all of 2025 with our Year in Review.